WO2007109248A3 - Traitement ou prévention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du récepteur de leukotriène et de la vitamine e - Google Patents

Traitement ou prévention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du récepteur de leukotriène et de la vitamine e Download PDF

Info

Publication number
WO2007109248A3
WO2007109248A3 PCT/US2007/006854 US2007006854W WO2007109248A3 WO 2007109248 A3 WO2007109248 A3 WO 2007109248A3 US 2007006854 W US2007006854 W US 2007006854W WO 2007109248 A3 WO2007109248 A3 WO 2007109248A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperpigmentation
vitamin
scarring
receptor antagonist
prevention
Prior art date
Application number
PCT/US2007/006854
Other languages
English (en)
Other versions
WO2007109248A2 (fr
Inventor
Larry Schlesinger
Original Assignee
Larry Schlesinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Larry Schlesinger filed Critical Larry Schlesinger
Priority to CA002646969A priority Critical patent/CA2646969A1/fr
Priority to AU2007227286A priority patent/AU2007227286A1/en
Priority to EP07753480A priority patent/EP1996185A2/fr
Publication of WO2007109248A2 publication Critical patent/WO2007109248A2/fr
Publication of WO2007109248A3 publication Critical patent/WO2007109248A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'administration combinée d'un antagoniste du récepteur de leukotriène et de la vitamine E afin de prévenir ou de traiter la cicatrisation et/ou une contracture capsulaire et/ou une hyperpigmentation.
PCT/US2007/006854 2006-03-20 2007-03-20 Traitement ou prévention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du récepteur de leukotriène et de la vitamine e WO2007109248A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002646969A CA2646969A1 (fr) 2006-03-20 2007-03-20 Traitement ou prevention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du recepteur de leukotriene et de la vitamine e
AU2007227286A AU2007227286A1 (en) 2006-03-20 2007-03-20 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin E
EP07753480A EP1996185A2 (fr) 2006-03-20 2007-03-20 Traitement ou prévention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du récepteur de leukotriène et de la vitamine e

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78339806P 2006-03-20 2006-03-20
US60/783,398 2006-03-20

Publications (2)

Publication Number Publication Date
WO2007109248A2 WO2007109248A2 (fr) 2007-09-27
WO2007109248A3 true WO2007109248A3 (fr) 2008-03-20

Family

ID=38523041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006854 WO2007109248A2 (fr) 2006-03-20 2007-03-20 Traitement ou prévention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du récepteur de leukotriène et de la vitamine e

Country Status (4)

Country Link
EP (1) EP1996185A2 (fr)
AU (1) AU2007227286A1 (fr)
CA (1) CA2646969A1 (fr)
WO (1) WO2007109248A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
WO2003074019A1 (fr) * 2002-03-06 2003-09-12 Showa Denko K.K. Composition cosmetique blanchissante
WO2003094882A1 (fr) * 2002-05-09 2003-11-20 Showa Denko K.K. Preparation externe de blanchiment de la peau
US6951869B2 (en) * 2002-02-26 2005-10-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US6951869B2 (en) * 2002-02-26 2005-10-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
WO2003074019A1 (fr) * 2002-03-06 2003-09-12 Showa Denko K.K. Composition cosmetique blanchissante
WO2003094882A1 (fr) * 2002-05-09 2003-11-20 Showa Denko K.K. Preparation externe de blanchiment de la peau

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAKER J.L.: "The Effectiveness of Alpha-Tocopherol (Vitamin E) in Reducing the Incidence of Spherical Contracture around Breast Implants", PLAST RECONSTR. SURG., vol. 68, no. 5, 1981, pages 696 - 699 *
FUNASAKA Y. ET AL.: "Depigmenting Effect of alpha-Tocopheryl Ferulate on Normal Human Melanocytes", PIGMENT CELL RES., vol. 13, no. SUPPL. 8, 2000, pages 170 - 174 *
MORELLI J.G. ET AL.: "Leukotriene B4-Induced Human Melanocyte Pigmentation and Leukotriene C4-Induced Human Melanocyte Growth Are Inhibited by Different Isoquinolinesulfonamides", J. INVEST. DERMATOL., vol. 98, no. 1, 1992, pages 55 - 58, XP008020580, DOI: doi:10.1111/1523-1747.ep12494602 *
REID R.R. ET AL.: "The Effect of Zafirlukast (Accolate) on Early Capsular Contracture in the Primary Augmentation Patient: A Pilot Study", AESTHETIC SURGERY JOURNAL, vol. 25, no. 1, 2005, pages 26 - 30, XP004753860, DOI: doi:10.1016/j.asj.2004.12.003 *
TOMITA Y. ET AL.: "Melanocyte-Stimulating Properties of Arachidonic Acid Metabolites: Possible Role in Postinflammatory Pigmentation", PIGMENT CELL RES., vol. 5, no. 5, PART 2, 1992, pages 357 - 361, XP008020760 *

Also Published As

Publication number Publication date
AU2007227286A1 (en) 2007-09-27
WO2007109248A2 (fr) 2007-09-27
CA2646969A1 (fr) 2007-09-27
EP1996185A2 (fr) 2008-12-03

Similar Documents

Publication Publication Date Title
WO2008122049A3 (fr) Procédés et compositions pour la réduction des effets secondaires des traitements thérapeutiques
WO2007048026A3 (fr) Antagonistes de peptide cgrp et conjugues
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
IL196571A0 (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
ZA200900228B (en) N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
WO2008030505A8 (fr) Procédés et compositions de traitement de neuropathies induites par des antibiotiques
WO2010060937A3 (fr) Combinaisons inhibitrices hsp90
MY148872A (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
MX277822B (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
EP2052251A4 (fr) Multithérapie avec antagoniste du récepteur 5-ht7 et inhibiteur du recaptage de la sérotonine
WO2008094969A3 (fr) Polychimiothérapie avec inhibiteurs de l'angiogenèse
MX2007008756A (es) Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
IL183557A0 (en) The use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
WO2008027013A3 (fr) Composition et procédé
WO2008057780A3 (fr) Administration transdermique de dérivés polaires de kétoprofène
WO2009031606A1 (fr) Agents thérapeutiques et prophylactiques pour l'arthrite
PL2146991T3 (pl) Pochodne triazolopirydyno-karboksamidów, ich wytwarzanie i zastosowanie terapeutyczne
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
IL194770A0 (en) 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine and its use as a medicament
WO2005099749A3 (fr) Methodes pour controler une angiogenese et une proliferation cellulaire
WO2011044523A3 (fr) Compositions et procédés destinés à traiter l'obésité
WO2010077976A3 (fr) Antagoniste du récepteur de la prokinéticine et ses utilisations
WO2008048996A3 (fr) Thérapie de combinaison séquentielle
WO2007109248A3 (fr) Traitement ou prévention de la cicatrisation, de contractures capsulaires et/ou d'une hyperpigmentation au moyen d'un antagoniste du récepteur de leukotriène et de la vitamine e
WO2009027955A3 (fr) Composition de détoxication et procédé de détoxication du corps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753480

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2646969

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007227286

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007753480

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007227286

Country of ref document: AU

Date of ref document: 20070320

Kind code of ref document: A